M.S. Gordon

1.1k total citations
89 papers, 686 citations indexed

About

M.S. Gordon is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Hematology. According to data from OpenAlex, M.S. Gordon has authored 89 papers receiving a total of 686 indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Molecular Biology, 34 papers in Pulmonary and Respiratory Medicine and 26 papers in Hematology. Recurrent topics in M.S. Gordon's work include Renal cell carcinoma treatment (24 papers), Renal and related cancers (14 papers) and Chronic Lymphocytic Leukemia Research (13 papers). M.S. Gordon is often cited by papers focused on Renal cell carcinoma treatment (24 papers), Renal and related cancers (14 papers) and Chronic Lymphocytic Leukemia Research (13 papers). M.S. Gordon collaborates with scholars based in United States. M.S. Gordon's co-authors include Patrick J. Loehrer, Peter H. O’Donnell, William W. Ho, Omar Kabbarah, Elaine T. Lam, Darlene Lu, Kent C. Shih, Isabelle Rooney, David S. Mendelson and Show Hong Duh and has published in prestigious journals such as Journal of Clinical Oncology, European Journal of Cancer and Therapeutic Drug Monitoring.

In The Last Decade

M.S. Gordon

86 papers receiving 661 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
M.S. Gordon United States 14 309 219 212 212 115 89 686
Kevin Yee United States 9 480 1.6× 362 1.7× 303 1.4× 499 2.4× 267 2.3× 12 1.2k
Anne-Marie O’Farrell United States 6 360 1.2× 113 0.5× 214 1.0× 332 1.6× 146 1.3× 6 758
Yu‐Nien Sun United States 13 298 1.0× 129 0.6× 206 1.0× 80 0.4× 49 0.4× 30 702
Angela Gernone Italy 9 342 1.1× 164 0.7× 265 1.3× 273 1.3× 69 0.6× 32 782
Michael Xiang United States 16 475 1.5× 295 1.3× 351 1.7× 104 0.5× 102 0.9× 68 1.1k
Steve Eppler United States 10 319 1.0× 267 1.2× 427 2.0× 60 0.3× 104 0.9× 19 947
Rebecca Wood United States 3 119 0.4× 116 0.5× 213 1.0× 237 1.1× 168 1.5× 4 563
Hazem El‐Osta United States 16 262 0.8× 234 1.1× 434 2.0× 52 0.2× 47 0.4× 35 893
Fabien Calvo France 7 761 2.5× 199 0.9× 345 1.6× 167 0.8× 110 1.0× 13 1.4k
Eren Demirhan United States 8 201 0.7× 678 3.1× 290 1.4× 151 0.7× 92 0.8× 15 955

Countries citing papers authored by M.S. Gordon

Since Specialization
Citations

This map shows the geographic impact of M.S. Gordon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M.S. Gordon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M.S. Gordon more than expected).

Fields of papers citing papers by M.S. Gordon

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M.S. Gordon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M.S. Gordon. The network helps show where M.S. Gordon may publish in the future.

Co-authorship network of co-authors of M.S. Gordon

This figure shows the co-authorship network connecting the top 25 collaborators of M.S. Gordon. A scholar is included among the top collaborators of M.S. Gordon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M.S. Gordon. M.S. Gordon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
O’Donnell, Peter H., M.S. Gordon, Kent C. Shih, et al.. (2012). 621 A Phase I Dose-escalation Study of MFGR1877S, a Human Monoclonal Anti-fibroblast Growth Factor Receptor 3 (FGFR3) Antibody, in Patients (pts) with Advanced Solid Tumors. European Journal of Cancer. 48. 191–192. 27 indexed citations
2.
Gordon, M.S.. (2010). Warfarin Genotyping Reduces Hospitalization Rates: Results From the MM-WES (Medco-Mayo Warfarin Effectiveness Study). Yearbook of Oncology. 2010. 2–3. 25 indexed citations
3.
Gordon, M.S.. (2010). Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia. Yearbook of Oncology. 2010. 142–143. 31 indexed citations
4.
Gordon, M.S.. (2010). Phase II Study of Axitinib in Sorafenib-Refractory Metastatic Renal Cell Carcinoma. Yearbook of Oncology. 2010. 104–105. 6 indexed citations
5.
6.
Gordon, M.S.. (2010). RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models. Yearbook of Oncology. 2010. 191–191. 2 indexed citations
7.
8.
Gordon, M.S.. (2008). Epidermal growth factor receptor inhibition sensitizes renal cell carcinoma cells to the cytotoxic effects of bortezomib. Yearbook of Oncology. 2008. 92–93. 1 indexed citations
9.
Gordon, M.S.. (2008). Intermediate comparison of partial nephrectomy and radiofrequency ablation for clinical T1a renal tumours. Yearbook of Oncology. 2008. 99–100. 6 indexed citations
10.
11.
12.
Gordon, M.S.. (2007). Surgical treatment of adrenal metastasis from renal cell carcinoma: a single-centre experience of 45 patients. Yearbook of Oncology. 2007. 116–118. 1 indexed citations
13.
Gordon, M.S.. (2007). Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. Yearbook of Oncology. 2007. 348–349. 11 indexed citations
14.
Gordon, M.S.. (2007). Dasatinib in Imatinib-Resistant Philadelphia Chromosome—Positive Leukemias. Yearbook of Oncology. 2007. 144–145. 5 indexed citations
15.
Gordon, M.S.. (2007). Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome—Positive ALL. Yearbook of Oncology. 2007. 145–146. 2 indexed citations
16.
17.
Gordon, M.S.. (2006). Palifermin for Oral Mucositis After Intensive Therapy for Hematologic Cancers. Yearbook of Oncology. 2006. 24–25. 1 indexed citations
18.
19.
20.
Azzazy, Hassan Mohamed El-Said, et al.. (1998). Abbott AxSYM Vancomycin II Assay: Multicenter Evaluation and Interference Studies. Therapeutic Drug Monitoring. 20(2). 202–208. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kevin Yee Breakdown of academic impact, for papers by Anne-Marie O’Farrell Breakdown of academic impact, for papers by Yu‐Nien Sun Breakdown of academic impact, for papers by Angela Gernone Breakdown of academic impact, for papers by Michael Xiang Breakdown of academic impact, for papers by Steve Eppler Breakdown of academic impact, for papers by Rebecca Wood Breakdown of academic impact, for papers by Hazem El‐Osta Breakdown of academic impact, for papers by Fabien Calvo Breakdown of academic impact, for papers by Eren Demirhan
Rankless by CCL
2026